Group 1 - The "Artificial Intelligence Medical Device Innovation Development Conference" was held in Shanghai, where the Artificial Intelligence Medical Device Alliance was officially established, aiming to address common challenges in data compliance and review processes for AI medical devices [1] - Zhonghui Medical, a leader in ultrasound treatment, was selected as one of the first members of the alliance, focusing on providing safer and more efficient treatment options for cancer patients through phased array focused ultrasound technology [1] - The Shanghai Xuhui District has achieved significant results in the biopharmaceutical industry during the 14th Five-Year Plan period, with 198 approved drug and medical device products, and an industry scale exceeding 100 billion yuan, including 8 AI-related products [1] Group 2 - Zhonghui Medical plans to leverage the alliance platform to efficiently connect with clinical resources, accelerate technology validation, and promote the construction of the MOS open platform to lower R&D barriers for partners [2] - The company aims to participate continuously in the integrated ecosystem of "R&D—Validation—Application—Promotion" and facilitate compliance data sharing to overcome the "last mile" challenge of AI medical devices from the lab to the clinic [2] - Zhonghui Medical is set to launch the world's first dual-energy phased array focused ultrasound treatment robot, which integrates various technologies and is expected to be applied in non-invasive clinical treatments for diseases such as breast cancer within one to two years [1]